Last checked at 28 Apr 2021 07:00
28 April 2021
Microsaic Systems plc
("Microsaic" or "Company")
Notice of Results and Investor Presentation
Microsaic, (AIM:MSYS) the micro-engineering, miniaturised chip-based mass spectrometry ("MS") developer for point-of-need analytical detection, confirms that it expects to announce its final results for the year ended 31 December 2020 ("FY20") on 4 May 2021.
The Company is pleased to announce that Glenn Tracey, CEO, and Bevan Metcalf, CFO, will provide a live presentation relating to the final results for FY20 via the Investor Meet Company platform on 4 May 2021 at 10:00am BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard until 9.00am BST the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Microsaic Systems plc via:
https://www.investormeetcompany.com/microsaic-systems-plc/register-investor
Investors who already follow Microsaic Systems plc on the Investor Meet Company platform will automatically be invited.
Microsaic Systems plc | Glenn Tracey, CEOBevan Metcalf, FD | +44 (0) 1483 751 577
|
N+1 Singer(Nominated Adviser& Joint Broker) | Aubrey Powell / George Tzimas /Tom Salvesen | +44 (0) 20 7496 3000 |
Turner Pope Investments (TPI) Limited (Joint Broker) | Andy Thacker / Zoe Alexander | +44 (0) 20 3657 0050 |
About Microsaic (www.microsaic.com)
Microsaic floated on AIM in 2011 to develop and commercialise micro-engineering chip-based mass spectrometry equipment. Having invested c. £30m over 20 years of development, Microsaic has a robust and innovative patent portfolio in cutting-edge technology designed and developed for "Industry 4.0" application. Microsaic serves markets in Human Health, Environmental Health and Diversified Industries. Microsaic's system solutions enable analytical detection and characterisation at the point-of-need, whether within a conventional laboratory setting, or within a bioprocessing facility for continuous MS detection data at multiple steps in the process workflow.
Microsaic's products and systems are commercially available through global markets via a network of regional and local partners, targeting its core laboratory, manufacturing and point of need applications.